Non-hypovascular Solid Pancreatic Lesions: Role of EUS

Role of EUS in Differential Diagnosis and Malignancy Prediction of Non-hypovascular Solid Pancreatic Lesions: A Prospective Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03738280

Acronym

LE-VASC

Enrollment

154

Registered

2018-11-13

Start date

2016-05-01

Completion date

2019-05-31

Last updated

2019-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endoscopic Ultrasound, Solid Pancreatic Neoplasms

Brief summary

Vascular pattern of solid pancreatic lesions (SPLs) has been investigated by different abdominal imaging modalities and by contrast-enhanced endoscopic ultrasonography (CE-EUS). Compared with surrounding pancreatic parenchyma three different patterns have been described: hypo-, iso-, and hypervascular. The majority of SPLs are hypovascular, and the diagnostic relevance of hypoenhanced pattern to predict pancreatic adenocarcinoma (PDAC) is well established. Differently, iso- and hypervascular pattern is not specific and can be expressed by several SPLs, with different clinical behavior and management. To date, poor is know about the role of EUS in differential diagnosis of non-hypovascular SPLs and features associated with malignancy.

Interventions

DIAGNOSTIC_TESTEndoscopic ultrasound-fine needle biopsy

Patients with non-hypovascular solid pancreatic lesion undergo endoscopic ultrasound-fine needle biopsy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Presence of one or more solid pancreatic lesions preliminary evaluated by contrast-enhanced computed tomography (CE-CT) and/or contrast enhanced magnetic resonance imaging (CE-MRI) reporting a non-hypovascular contrast pattern (e.g., iso- or hypervascular).

Exclusion criteria

* Patients with associated chronic pancreatitis features (e.g., pancreatic calcifications) * Lesion with hypovascular pattern at CE-EUS. * Lesion not found or non pancreatic at EUS. * Patients refusing to be included in the study

Design outcomes

Primary

Measure	Time frame	Description
Upstream dilation of the main pancreatic duct	6 months	Percentage of cases with upstream dilation of main pancreatic duct will be recorded.
Vascular pattern (iso or hypervascular)	6 months	Percentage of cases with iso-vascular or hyper-vascular pattern will be recorded.
Lesion borders (smooth or irregular)	6 months	Percentage of cases with smooth or irregular borders will be recorded.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026